MedTrace Logo

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

NCT05503953 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 306

Last updated 2022-08-18

No results posted yet for this study

Summary

A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS

Conditions

  • Essential Hypertension

Interventions

DRUG

AGSAVI

Uptitation

DRUG

AGLS

Uptitration

Sponsors & Collaborators

  • Daehwa Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Ahn-Gook Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-05
Primary Completion
2024-02-29
Completion
2024-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05503953 on ClinicalTrials.gov